Recent Trends in Nanoparticles Based Drug Delivery for Tuberculosis Treatment

Pachouri Chandni, P. Bharat, Shroti Sandhya, S. Sandeep, P. Archna
{"title":"Recent Trends in Nanoparticles Based Drug Delivery for Tuberculosis Treatment","authors":"Pachouri Chandni, P. Bharat, Shroti Sandhya, S. Sandeep, P. Archna","doi":"10.23937/2378-3664.1410035","DOIUrl":null,"url":null,"abstract":"Current treatment therapeutic approach for tuberculosis is the administration of first line drugs in the form of tablets and capsules for 4-6 months however; this approach leads to sever adverse effect. Therefore, present study was designed to achieving local and sustained targeting of ant tuberculosis drugs in order to reduce dose n frequency. Nanoparticles (NPs) have been found to be potential targeted and controlled release drug delivery systems. Various drugs can be loaded in the NPs to achieve targeted delivery. Nanoparticles of antituberculosis drugs are generally prepared by using chitosan and PLGA polymer. Nanoparticles of Chitosan being biodegradable, biocompatible, less toxic and easy to prepare, are an effective and potential tool for drug delivery. The selection of a nanoencapsulation technique should consider drug property, nanoparticle quality, scale-up feasibility, manufacturing costs, personnel safety, environmental impact, waste disposal, and the like. In recent years, there have been a plethora of nanoengineering approaches for the development of poly (lactide-co-glycolide) (PLGA) nanoparticulate carrier systems. However, overlooking the multifaceted issues in the preparation and characterization of PLGA-based nanoparticles. Relevant information might be helpful to those who prepare and develop nanoparticles of ant tuberculosis drugs that meet their specific demands.","PeriodicalId":91094,"journal":{"name":"International journal of medical nano research","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of medical nano research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23937/2378-3664.1410035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Current treatment therapeutic approach for tuberculosis is the administration of first line drugs in the form of tablets and capsules for 4-6 months however; this approach leads to sever adverse effect. Therefore, present study was designed to achieving local and sustained targeting of ant tuberculosis drugs in order to reduce dose n frequency. Nanoparticles (NPs) have been found to be potential targeted and controlled release drug delivery systems. Various drugs can be loaded in the NPs to achieve targeted delivery. Nanoparticles of antituberculosis drugs are generally prepared by using chitosan and PLGA polymer. Nanoparticles of Chitosan being biodegradable, biocompatible, less toxic and easy to prepare, are an effective and potential tool for drug delivery. The selection of a nanoencapsulation technique should consider drug property, nanoparticle quality, scale-up feasibility, manufacturing costs, personnel safety, environmental impact, waste disposal, and the like. In recent years, there have been a plethora of nanoengineering approaches for the development of poly (lactide-co-glycolide) (PLGA) nanoparticulate carrier systems. However, overlooking the multifaceted issues in the preparation and characterization of PLGA-based nanoparticles. Relevant information might be helpful to those who prepare and develop nanoparticles of ant tuberculosis drugs that meet their specific demands.
纳米颗粒给药结核病治疗的最新趋势
然而,目前结核病的治疗方法是以片剂和胶囊形式给予一线药物4-6个月;这种做法会导致严重的不良影响。因此,本研究旨在实现抗结核药物的局部和持续靶向,以减少剂量和频率。纳米颗粒(NPs)是一种潜在的靶向和控释药物递送系统。NPs中可装载多种药物,实现靶向给药。抗结核药物的纳米颗粒一般是由壳聚糖和聚乳酸聚合物制备的。壳聚糖纳米颗粒具有可生物降解、生物相容性好、毒性小、制备简单等优点,是一种有效的、有潜力的药物递送工具。纳米胶囊技术的选择应考虑药物性质、纳米颗粒质量、规模化可行性、制造成本、人员安全、环境影响、废物处理等因素。近年来,已经有了大量的纳米工程方法来开发聚乳酸-羟基乙酸酯(PLGA)纳米颗粒载体体系。然而,忽略了制备和表征plga基纳米颗粒的多方面问题。相关信息可能对那些制备和开发符合其特定需求的抗结核药物纳米颗粒的人有所帮助。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信